Tier 2 — strong

Effectiveness of the quercetin use in patients with COVID-19 with concomitant type 2 diabetes mellitus

Zoriana Tylishchak, Oleksandra Pryshliak, Oleksandr Boichuk, Sergiy Fedorov, Andrii Protsyk, Taras Kobryn, Ruslan Miziuk
Wiadomosci lekarskie (Warsaw, Poland : 1960) 2024 77(10):1962-1968

Bibliography

PubMed
PMID 39661889
DOI
10.36740/WLek/191875
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignComparative hospitalized COVID-19 study
ModelHuman intervention research
Sample60 patients with type 2 diabetes; 30 per group
InterventionIntravenous quercetin 0.5 g/day plus protocol care versus protocol care
Duration10 days
EndpointsInflammatory measures

What the study showed, in plain terms

Published in 2024, this source examined immunity and respiratory health. Design: Comparative hospitalized COVID-19 study. Sample/model: 60 patients with type 2 diabetes; 30 per group. The exposure or intervention was Intravenous quercetin 0.5 g/day plus protocol care versus protocol care. Follow-up or treatment period: 10 days.

The authors report improved inflammatory, oxygenation, and capillaroscopy measures in the adjunct group.

Allocation methods and robust between-group clinical event estimates are not established in the abstract. Intravenous treatment is not oral supplementation, and thrombosis prevention was not demonstrated.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Immune Health, Colds and COVID-19. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • The authors report improved inflammatory, oxygenation, and capillaroscopy measures in the adjunct group.
  • The recorded outcome domains were Inflammatory measures.
  • The result applies to the tested exposure: Intravenous quercetin 0.5 g/day plus protocol care versus protocol care; 10 days.

What this study can and cannot tell us

  • Allocation methods and robust between-group clinical event estimates are not established in the abstract. Intravenous treatment is not oral supplementation, and thrombosis prevention was not demonstrated.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 1
Quercetin for the treatment of COVID-19 patients: A systematic review and meta-analysis
Huzaifa Ahmad Cheema et al. · Reviews in medical virology · 2023
Tier 1
The effect of quercetin supplementation on clinical outcomes in COVID-19 patients: A systematic review and meta-analysis
Somayeh Ziaei et al. · Food science & nutrition · 2023
Tier 2
Potential Adjunctive Effects of Quercetin-Curcumin Co-Supplementation in Adults with Mild-to-Moderate Long COVID: Results from a Pragmatic Exploratory Real-World Clinical Study
Amjad Khan et al. · Pharmaceuticals (Basel, Switzerland) · 2026
Tier 2
Quercetin–bromelain supplementation and clinical outcomes of COVID-19: a randomized, double-blind, placebo-controlled trial in hospitalized patients in Tunisia
Marwa Gargouri et al. · BMC Pharmacology and Toxicology · 2026
Tier 2
Effect of oral treatment with quercetin on inflammatory and oxidative stress markers in patients with chronic obstructive pulmonary disease
Shivani Patel et al. · Pharmacological research. Natural products · 2025

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology